No connection

Search Results

NCEL vs SINT

NCEL
NewcelX Ltd.
BEARISH
Price
$2.52
Market Cap
$11.5M
Sector
Healthcare
AI Confidence
95%
SINT
Sintx Technologies, Inc.
BEARISH
Price
$2.69
Market Cap
$11.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
NCEL
--
SINT
--
Forward P/E
NCEL
--
SINT
-1.53
P/B Ratio
NCEL
-0.22
SINT
3.64
P/S Ratio
NCEL
--
SINT
10.89
EV/EBITDA
NCEL
--
SINT
-1.0

Profitability

Gross Margin
NCEL
0.0%
SINT
45.28%
Operating Margin
NCEL
0.0%
SINT
-787.59%
Profit Margin
NCEL
0.0%
SINT
0.0%
ROE
NCEL
--
SINT
-303.8%
ROA
NCEL
-155.19%
SINT
-69.8%

Growth

Revenue Growth
NCEL
--
SINT
-46.5%
Earnings Growth
NCEL
--
SINT
--

Financial Health

Debt/Equity
NCEL
--
SINT
1.11
Current Ratio
NCEL
0.02
SINT
1.51
Quick Ratio
NCEL
0.02
SINT
1.16

Dividends

Dividend Yield
NCEL
--
SINT
--
Payout Ratio
NCEL
0.0%
SINT
0.0%

AI Verdict

NCEL BEARISH

NCEL exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing an acute liquidity crisis with a Current Ratio of 0.02, suggesting an inability to meet short-term obligations. With a negative Price/Book ratio (-0.22) and a catastrophic 5-year price decline of 99.8%, the firm is effectively operating with negative equity. The lack of revenue and an ROA of -155.19% point toward a high probability of insolvency or imminent dilution.

Strengths
Recent short-term price bounce (+21.1% over 1 week)
Operates in the high-growth Biotechnology sector
Low absolute share price may attract speculative day-traders
Risks
Extreme liquidity risk (Current Ratio 0.02)
Negative shareholder equity (Price/Book -0.22)
Severe fundamental deterioration (Piotroski 1/9)
SINT BEARISH

SINT exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -787.59%. The company is experiencing a collapse in its top line with YoY revenue growth at -46.50% and a consistent track record of missing earnings estimates (0/4 beats in the last year). Despite a 'Strong Buy' analyst consensus and a target price of $10.17, the fundamental data suggests a company in a death spiral with a 5-year price change of -100%. The disconnect between analyst optimism and the deterministic health scores indicates extreme speculative risk.

Strengths
Positive Gross Margin (45.28%) suggesting some product-level viability
Current Ratio of 1.51 provides a minimal short-term liquidity buffer
Quick Ratio of 1.16 indicates ability to cover immediate liabilities
Risks
Severe revenue contraction (-46.50% YoY)
Extreme operational inefficiency (Operating Margin -787.59%)
Massive equity erosion (ROE -303.80%)

Compare Another Pair

NCEL vs SINT: Head-to-Head Comparison

This page compares NewcelX Ltd. (NCEL) and Sintx Technologies, Inc. (SINT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile